Cotización Fidelity Sus Research En... - FUSR

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

8.93

Postura de Compra

9.06

Postura de Venta

9.147

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Precio Anterior

8.93

Precio de Apertura

Hora

Última hora de negociación

Volumen promedio (3 m)

Volumen financiero

Precio Promedio Ponderado

Form 8-K - Current report

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with...

Form S-3 - Registration statement under Securities Act of 1933

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events...

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Expansion of Leadership Team

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
NCNCnoco noco Inc	US$ 0.28 (83.01%)	299.32M
WINTWindtree Therapeutics Inc	US$ 9.19 (61.80%)	682.68k
NUZENuZee Inc	US$ 5.915 (59.86%)	36.61M
PMECPrimech Holdings Ltd	US$ 0.8299 (57.72%)	99.13M
LSHLakeside Holding Ltd	US$ 3.70 (56.12%)	28.51M
CETUUCetus Capital Acquisition Corporation	US$ 2.60 (-62.86%)	3.1k
CETUCetus Capital Acquisition Corporation	US$ 2.22 (-62.18%)	537.72k
IMNNImunon Inc	US$ 1.33 (-59.94%)	16.24M
FGENFibroGen Inc	US$ 0.5417 (-47.41%)	16.48M
VCNXVaccinex Inc	US$ 5.09 (-36.85%)	1.06M
NVDANVIDIA Corporation	US$ 117.02 (12.81%)	473.3M
NCNCnoco noco Inc	US$ 0.28 (83.01%)	299.33M
SQQQProShares UltraPro Short QQQ	US$ 8.59 (-8.91%)	244.35M
PRSTPresto Technologies Inc	US$ 0.038406 (9.73%)	207.14M
FFIEFaraday Future Intelligent Electric Inc	US$ 0.343 (8.54%)	145.24M